Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)-Reference-Cited by-同舟云学术

Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)

Published:2015-11-06 Issue:1 Volume:96 Page:9-18
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Cramer Paula¹,Langerbeins Petra¹,Eichhorst Barbara¹,Hallek Michael¹²

Affiliation:

1. Department I of Internal Medicine; Center of Integrated Oncology Cologne-Bonn and German CLL Study Group; University of Cologne; Cologne Germany

2. CECAD - Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases; University of Cologne; Cologne Germany

Funder

Celgene

Gilead Sciences

GlaxoSmithKline

F. Hoffman-La Roche

Janssen-Cilag

Mundipharma

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12678/fullpdf

Reference91 articles.

1. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001;Morton;Blood,2006

2. Disease burden of chronic lymphocytic leukaemia within the European Union;Watson;Eur J Haematol,2008

3. Cancer statistics, 2007;Jemal;CA Cancer J Clin,2007

4. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients;Molica;Leuk Lymphoma,2006

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

2. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study;British Journal of Haematology;2021-02-19

3. Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients;Iraqi Journal of Hematology;2021

4. DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia;International Journal of Molecular Sciences;2020-10-16

5. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada;Leukemia Research;2020-04